U.S. Biotech Company, Moderna, has continues to reap the rewards of its COVID-19 vaccine.
In the final quarter of 2021, the company had achieved net profits of $4.9 billion, it announced on Thursday.
In the last fiscal year, Moderna made a surplus of $12.2 billion, although the high research and development costs of the previous year had led to losses of $747 million.
However, all in all, the high demand for its vaccine led to revenues of $18.5 billion for 2021, up from $803 million the previous year.
Moderna’ signed advance purchase agreements for 2022 are valued at $19 billion, up from a predicted $18.5 billion in January.
The company holds additional signed options of approximately $3 billion.
READ ALSO: 3.5GHz Spectrum: MTN, Mafab pay $273.6m for licences
In comparison, rival company Pfizer expects revenues for its COVID vaccine of $32 billion for 2022.
The U.S-based pharmaceutical company developed its vaccine together with its German partner Biotech.
President Bola Tinubu has assured local and foreign investors that Nigeria remains open for business,…
A British man in his 60s has pleaded guilty to drugging and raping his wife…
The Federal Government has assured workers of King’s College, Lagos, that their jobs are secure…
The Federal Government has met with staff unions over issues surrounding the proposed concession of…
The Anambra State Government says it is still servicing loans obtained by previous administrations, including…
The Nigeria Security and Civil Defence Corps (NSCDC) has arrested nine men accused of removing…
This website uses cookies.